SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report.
Marouf Mouhammad AlhalabiKamal Alaa EddinFadwa AliAhmad AbbasPublished in: Medicine (2022)
It is unclear whether anti-TNF-α treatment improves or deteriorates COVID-19 patient outcomes, and this case demonstrates that infliximab can be used safely. Current guidelines make a weak recommendation to avoid using anti-TNFα agents in the presence of acute COVID-19 infection. There is an urgent need for research on biologics therapy.
Keyphrases
- sars cov
- ulcerative colitis
- respiratory failure
- liver failure
- coronavirus disease
- respiratory syndrome coronavirus
- drug induced
- rheumatoid arthritis
- aortic dissection
- hepatitis b virus
- early onset
- extracorporeal membrane oxygenation
- clinical practice
- acute respiratory distress syndrome
- mechanical ventilation
- combination therapy
- replacement therapy